lansoprazole has been researched along with Barrett Epithelium in 25 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease." | 9.12 | Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. ( De Micheli, E; Frazzoni, M; Manno, M; Savarino, V, 2006) |
| "To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease." | 5.12 | Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. ( De Micheli, E; Frazzoni, M; Manno, M; Savarino, V, 2006) |
| "Patients with Barrett's oesophagus received open-label consecutive treatment (a 15-day period of once-daily dosing followed by a 10-day period of twice-daily dosing) with esomeprazole (40-mg capsules) and lansoprazole (30-mg capsules) in random order with no washouts." | 2.74 | Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole. ( Barker, PN; Silberg, DG; Spechler, SJ, 2009) |
| "Patients with Barrett's esophagus at least 3 cm long and with specialized columnar epithelium were treated with 60 mg of lansoprazole each morning." | 2.67 | Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. ( Sampliner, RE, 1994) |
| "The treatment of Barrett's esophagus is controversial." | 2.43 | [The clinical strategy for the Barrett's esophagus]. ( Goto, H; Kitabatake, S; Niwa, Y, 2005) |
| "To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects." | 2.43 | Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "The length of the Barrett's esophagus segment and the size of a hiatal hernia are associated with the risk of developing high-grade dysplasia and esophageal adenocarcinoma." | 2.42 | Reflux disease and Barrett's esophagus. ( Haag, S; Holtmann, G, 2003) |
| "Thirty-two patients with long-segment Barrett esophagus who were asymptomatic with PPIs." | 1.32 | Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. ( Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS, 2004) |
| " The two groups were not different in regard to their symptom frequency and severity before therapy, amount of lansoprazole dosage required to eliminate symptoms, length of Barrett's metaplasia, presence of hiatal hernia, lower esophageal sphincter resting tone and length, or esophageal peristaltic function." | 1.30 | Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. ( Ouatu-Lascar, R; Triadafilopoulos, G, 1998) |
| "Argon plasma coagulation in an acid-controlled environment was both efficacious and safe in the treatment of Barrett's esophagus." | 1.30 | The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. ( Grade, AJ; Medlin, SM; Ramirez, FC; Shah, IA, 1999) |
| "26 patients with a Barrett's esophagus of at least 2 cm length (medium 4." | 1.30 | [Treatment of Barrett esophagus with argon plasma coagulation with acid suppression--a prospective study]. ( Jakobs, R; Maass, S; Martin, WR; Riemann, JF; Spiethoff, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (44.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babic, Z | 1 |
| Bogdanovic, Z | 1 |
| Dorosulic, Z | 1 |
| Petrovic, Z | 1 |
| Kujundzic, M | 1 |
| Banic, M | 1 |
| Marusic, M | 1 |
| Heinzl, R | 1 |
| Bilić, B | 1 |
| Andabak, M | 1 |
| Pellicano, R | 1 |
| Spechler, SJ | 1 |
| Barker, PN | 1 |
| Silberg, DG | 1 |
| Miyashita, T | 1 |
| Shah, FA | 1 |
| Harmon, JW | 1 |
| Marti, GP | 1 |
| Matsui, D | 1 |
| Okamoto, K | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Nakagawara, H | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Murakami, M | 1 |
| Ninomiya, I | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Haag, S | 1 |
| Holtmann, G | 1 |
| Sarela, AI | 1 |
| Hick, DG | 1 |
| Verbeke, CS | 1 |
| Casey, JF | 1 |
| Guillou, PJ | 1 |
| Clark, GW | 1 |
| Gerson, LB | 1 |
| Shetler, K | 1 |
| Triadafilopoulos, G | 3 |
| Kitabatake, S | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Frazzoni, M | 1 |
| Manno, M | 1 |
| De Micheli, E | 1 |
| Savarino, V | 2 |
| Cooper, BT | 1 |
| Chapman, W | 1 |
| Neumann, CS | 1 |
| Gearty, JC | 1 |
| Guimarães, EV | 1 |
| Marguet, C | 1 |
| Camargos, PA | 1 |
| Mela, GS | 1 |
| Zentilin, P | 1 |
| Celle, G | 1 |
| Vigneri, S | 1 |
| Sampliner, RE | 2 |
| Sontag, SJ | 1 |
| Schnell, TG | 1 |
| Chejfec, G | 1 |
| Kurucar, C | 1 |
| Karpf, J | 1 |
| Levine, G | 1 |
| Bozymski, EM | 1 |
| Shaheen, NJ | 1 |
| Sharma, P | 1 |
| Camargo, E | 1 |
| Castell, DO | 4 |
| Katz, PO | 2 |
| Ouatu-Lascar, R | 2 |
| Grade, AJ | 1 |
| Shah, IA | 1 |
| Medlin, SM | 1 |
| Ramirez, FC | 1 |
| Fitzgerald, RC | 1 |
| Martin, WR | 1 |
| Jakobs, R | 1 |
| Spiethoff, A | 1 |
| Maass, S | 1 |
| Riemann, JF | 1 |
| Katzka, DA | 2 |
| Stolte, M | 1 |
| Vieth, M | 1 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Seifert, E | 1 |
| Srinivasan, R | 1 |
| Ramakrishnan, A | 1 |
| Vela, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project[NCT00586404] | 1,250 participants (Actual) | Observational | 2007-11-30 | Terminated (stopped due to lack of enrollment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for lansoprazole and Barrett Epithelium
| Article | Year |
|---|---|
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esop | 2013 |
Reflux disease and Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Endos | 2003 |
[The clinical strategy for the Barrett's esophagus].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Ba | 2005 |
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre | 2006 |
Aggressive acid control: minimizing progression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Enzyme Inhibitors; Gastroesophageal Refl | 2001 |
8 trials available for lansoprazole and Barrett Epithelium
| Article | Year |
|---|---|
One year treatment of Barrett's oesophagus with proton pump inhibitors (a multi-center study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Epithelial Cells; Esophagoscopy; Esophag | 2015 |
Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Cross-Ov | 2009 |
Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Barrett Esophagus; Benzimidazoles; Esophageal pH Moni | 2005 |
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Esomeprazole; Esophag | 2006 |
Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Epitheli | 1994 |
Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Double-Blind Method; Enzyme Inhibitors; | 1997 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Endoscop | 2001 |
11 other studies available for lansoprazole and Barrett Epithelium
| Article | Year |
|---|---|
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; | 2004 |
Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Eso | 2006 |
Once or twice daily doses of proton pump inhibitor in treating Barrett's esophagus?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Drug Administration S | 1995 |
Barrett's esophagus: acid suppression, but no regression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Gastric Acid; Humans; | 1997 |
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophag | 1997 |
Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Circadian Rhythm; Dru | 1997 |
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagus; Fema | 1998 |
The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Endoscopes; E | 1999 |
Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett | 1999 |
[Treatment of Barrett esophagus with argon plasma coagulation with acid suppression--a prospective study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Combined | 1999 |
Importance of adequate acid suppression in the management of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Carrier Proteins; Cel | 1999 |